Search Results

<< Go back to the Podcast page EPISODE 13: NET ONCOLOGY Download a Transcript of this Episode >> ABOUT THIS EPISODE Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. MEET DR. JUN GONG Dr. Jun Gong is a medical oncologist of the Gastrointestinal Disease Research and Carcinoid and Neuroendocrine Tumors Group in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. His primary clinical interests are in gastrointestinal (GI) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, and radiology. He is focused on translational and clinical cancer research in early therapeutic trials and biomarker development to improve patient outcomes in GI cancers. TOP 10 NET ONCOLOGY QUESTIONS 1. Which is better -- if the tumor is expressing somatostatin on its receptors by DOTATATE scan or biomarker in tissue biopsy? 2. Since the somatostatin analogues bind to somatostatin receptors, can NET patients take “statin” medications for high cholesterol? 3. Is there a link between psychiatric medications and NETS? Can someone with NET take selective serotonin receptor inhibitors SSRI or SNRI? 4. What is the difference between genetic and genomic testing? When would you do genetic screening/testing and when would you do genomic testing/tumor sequencing? 5. Is it possible to find NET markers on serum or blood by using mass spectrum without biopsies? Is there a promising liquid biopsy? 6. How often should full body scans be done to discover metastases to other body parts? 7. Can well differentiated tumors become poorly differentiated? 8. Can NETs produce multiple hormones? Should one try to control any production of any hormones for general prevention? Should we control serotonin production generally? 9. How aggressive should you be to seek out new treatments when tumor burden is stable? (Some patients want to get rid of tumors so side effects of tumors are lessened.) 10. How common is having issues with liver functionality? What are the signs of liver failure due to tumor burden? DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC << Back SWOG S2012 - Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung CLINICALTRIALS.GOV IDENTIFIER: NCT05058651 DRUG/TREATMENT: Atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) PHASE: II/III STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=3YGASJXkSxI Dr. David Zhen Discusses SWOG S2012 Immunotherapy (atezolizumab) DESCRIPTION: This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here . CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. Principal Investigator: David B. Zhen, MD Southwest Oncology Group

Join NCF for Dec2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page COMPREHENSIVE GUIDE TO LUNG NEUROENDOCRINE CANCERS This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoid and Atypical Carcinoid. Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. Watch the session that pertains to your diagnosis. Session A: "Typical Carcinoid & Atypical Carcinoid" https://www.youtube.com/watch?v=owZRDf3ISM4 Session B: "Large Cell Neuroendocrine Carcinoma & Small Cell Lung Cancer" https://www.youtube.com/watch?v=LxXdXMKpaCo Click here for the presentation slides from the above video. ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. 'OUR CANCER STORIES' SURVEY Researchers are currently conducting an international study approved by the NUS Ethics Committee (NUS-IRB-2023-320) to examine the relationship between emotional well-being and recovery for cancer patients. Our Cancer Stories' goal is to gather anonymous insights from individuals (aged 30-70) diagnosed with prostate and lung cancer about their personal experiences. To ensure the success of this research, they are seeking cancer patients willing to share their stories through an online survey with the option of reimbursement of $20 USD upon completion. This is a confidential, online survey that will take about 30 minutes to complete. Survey responses will be used to create stories that will be published on a website called Our Cancer Stories ( www.ourcancerstories.com ). These stories are aimed at providing readers (e.g. cancer patients, survivors, caregivers, and those with loved ones affected by cancer) with information useful in making informed decisions in fighting cancer, while providing comfort and solidarity. Take the Survey The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism << Back upLIFT: A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (Tumor HI) IDENTIFIER ( ClinicalTrials.gov ) : NCT06881992 DRUG/TREATMENT : Ersodetug PHASE : 3 STATUS : Recruiting SPONSOR : Rezolute DESCRIPTION: upLIFT Study Interim Update June 2, 2026 Rezolute has shared an interim update from the upLIFT clinical trial, which is studying an investigational therapy called ersodetug for people with Tumor Hyperinsulinism (Tumor HI). The study is now halfway through enrollment, with 8 of a planned 16 participants enrolled. Of those 8 participants, 6 have met the study's primary endpoint — a reduction of at least 50% in the intravenous (IV) glucose needed to maintain stable blood sugar levels. All 6 were also able to discontinue IV glucose entirely while receiving ersodetug. No drug-related side effects have been reported to date. Participants who complete the initial 8-week treatment period have the option to continue in a 6-month extended phase. Full topline results from the completed study are expected in the second half of 2026. Please note: ersodetug is an investigational therapy that has not yet been reviewed or approved by any regulatory health authority. Read the full press release here. Rezolute is a late-stage rare disease company focused on substantially improving the quality of life for individuals living with hyperinsulinism (HI) and is now enrolling participants in the upLIFT study, a phase 3 clinical trial that is testing whether or not a new therapy, called ersodetug , can safely reduce hypoglycemia in adults with tumor HI. In tumor HI, certain tumors (lumps or abnormal cell growths) in the pancreas or other parts of the body make too much insulin or a similar protein called insulin-like growth factor-2 (IGF-2). Insulinomas are a rare type of neuroendocrine tumor that usually form from the insulin-secreting cells in the pancreas. Non-islet cell tumor hypoglycemia (sometimes called “Doege-Potter syndrome” or “paraneoplastic hypoglycemia”) is a rare condition where certain tumors outside the pancreas make too much hormone growth factors that can act like insulin. Both types of tumors can lead to very low blood sugar levels, a severe and potentially life-threatening complication of overactivation of the insulin receptor. Hypoglycemia can result in neurologic and cognitive problems as well as other serious health complications and may make it hard for people with tumor HI to stay healthy enough to continue their cancer treatments. We know that patients facing these complications often have complex needs and limited treatment options. We believe collaboration between patient advocacy organizations is essential to ensure patients receive the best possible support and access to care. This study is open to people 18 and older who have a type of tumor that causes tumor HI and are still experiencing frequent, serious low blood sugar levels, even with standard treatment. To learn more about the study or potential participation please talk to your doctor or visit upliftstudy.com or clinicaltrials.gov . You may also contact patient affairs via email at patient-affairs@rezolutebio.com for further assistance, if needed. Please note that ersodetug is still under investigation and has not been approved by any health authority. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Name: Rezolute Clinical Trial Phone Number: 650-206-4507 Email: patient-affairs@rezolutebio.com (primary contact). You may also reach out to clinicaltrials@rezolutebio.com . This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. RELATED RESOURCES CancerHypoglycemia.com This is a valuable resource for physicians as we continue to build educational content in non-islet cell tumor hypoglycemia (NICTH). Key elements of the site focus on: Pathophysiology Presentation and diagnosis Limitations in current management The impact of living with NICTH Resources and FAQs

<< Go back to the Podcast page EPISODE 48 - NEN TREATMENTS: FOCUS ON DLL3 Download a Transcript of this Episode >>> ABOUT THIS EPISODE DLL3 is emerging as a promising new target for neuroendocrine cancers. In this episode, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explains what DLL3 is, how it works, who might benefit, and what current clinical trials are teaching us. He breaks down the science, treatment options, and future directions in a way that is clear, approachable, and designed to help patients and families better understand this developing area of care. MEET DR. ROHIT THUMMALAPALLI Rohit Thummalapalli is a gastrointestinal medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center specializing in clinical care and research in patients with neuroendocrine and biliary tract cancers. Originally from Florida, Dr. Thummalapalli completed medical training at Harvard and Johns Hopkins before arriving at MSK as a medical oncology fellow in 2021, and started on faculty in 2024. TOP TEN QUESTIONS: Understanding the Basics What is immunotherapy? How does immunotherapy work? What is DLL3? How does it work in the context of neuroendocrine cancer? How is DLL-targeted therapy similar to or different from other types of immunotherapy? Is there evidence that one works better than another? Indications, Use, Access & Availability When is DLL3 used in neuroendocrine cancers? What types of neuroendocrine cancer might express DLL3? How does someone know if this is a potential treatment option for them? c. At what point in a patient’s treatment journey might DLL3 be considered? d. How and where DLL3 is available for neuroendocrine cancer patients? What are other ways, if any, to access DLL3? Testing for DLL3 Expression How does someone find out if their tumors express DLL3 receptors? How & where is DLL3 expression tested? It it tested through tissue samples, imaging, or something else? Is there a minimal level of DLL3 expression that is required to receive the treatment? (Does the threshold vary by trial?) Does the level of DLL3 expression differ by institution? Does the level of DLL3 expression predict how well someone might respond to treatment? Can the tumor expression of DLL3 vary from tumor to tumor? Can it vary over time, meaning can tumors gain or lose expression? Do you measure the DLL3 expression following treatment? Treatment Considerations How effective is DLL3-targeted therapy in neuroendocrine cancers? What is the goal of treatment with DLL3 – shrinkage, stabilization, symptom relief? How long is it expected to work? How do you measure the response to DLL3 treatment? Can DLL3 be combined with other therapies? Decision-Making and Patient Counseling How do you decide when to offer DLL3 for someone with neuroendocrine cancer? What factors or prior treatments might make someone ineligible for DLL3 therapy? Could receiving DLL3 exclude a patient from other treatments or clinical trials? How do you counsel patients who are considering DLL3? What should they know about how the treatment is given, possible side effects, and what’s known (or unknown) about long-term safety? What should one expect in terms of frequency of visits, hospitalization and side effects? Can someone still work while receiving DLL3? Looking Ahead What are the key questions you hope to answer about DLL3 in the next year? What do you hope to learn over the next 3 to 5 years? RESOURCES LISTEN Neuroendocrine Cancer Foundation Podcast Episode 36: NEN Treatments: Focus on Immunotherapy EXPLORE Clinical Trials Guide: Immunotherapy READ Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) (May 28, 2025) Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial (May 28, 2025) Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms - JCO Precision Oncology, November 20, 2025 WATCH Dr. Strosberg on Research Clarifying the Role of Obrixtamig in SCLC and Other Neuroendocrine Cancers (May 5, 2025) Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers (May 5, 2025) IMMUNOTHERAPY-BASED DLL3-TARGETED CLINICAL TRIALS Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms https://www.youtube.com/watch?v=HJCZzlD_kq8 NOVEL NON-IMMUNOTHERAPY-BASED DLL3-TARGETED CLINICAL TRIALS Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody A Study of ZL-1310 in Participants With Selected Solid Tumors https://www.youtube.com/watch?v=RQF3krrFx_g 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy https://www.youtube.com/watch?v=PDR0flgpAXE DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Alpha PRRT with Pb-212 VMT << Back Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT) IDENTIFIER ( ClinicalTrials.gov ) : NCT05636618 DRUG/TREATMENT : Alpha PRRT with 212Pb VMT PHASE : 1 / 2A STATUS : Recruiting SPONSOR : Perspective Therapeutics DESCRIPTION: https://www.youtube.com/watch?v=kOmdkMwoceQ June 2024: Dr. Aman Chauhan discusses the Alpha PRRT with Pb-212 VMT study. Perspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT). During phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose. Phase 1 studies the side effects, safety, and dosimetry. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Markus Puhlmann, MD, MBA at Perspective Therapeutics EMAIL: mpuhlmann@perspectivetherapeutics.com PHONE: (319) 665-2150

<< Go back to the Podcast page EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutchinson Cancer Center in Seattle answers 10 common questions about small bowel NETs. MEET DR. DAVID B. ZHEN Dr. David Zhen is a medical oncologist who specializes in treating patients with gastrointestinal cancers. His research centers around the development of clinical trials evaluating new therapies and combination approaches for the treatment of patients with gastrointestinal cancers, particularly for neuroendocrine and gastroesophageal cancers. He is also conducting research to understand the interactions of the immune system in gastrointestinal cancers and how this can be manipulated to improve upon the response to immunotherapy drugs called checkpoint inhibitors, which block a braking system that cancers use to tamp down the immune response. TOP 10 QUESTIONS 1. What are small bowel NETs? Where are they located? 2. How are small bowel NETs found? What are the symptoms of a small bowel NET? 3. What types of labs, scans, or testing is done to determine if someone has a small bowel NET? Why are small bowel NETs not found in routine endoscopy or colonoscopy? 4. What are some ways that small bowel NETs differ from other types of NETs? What makes small bowel NETs unique from other types of NETs? 5. How do you decide if the small bowel NET(s) can be surgically removed? What type of surgeon would make that determination? 6. How are small bowel NETs treated medically? 7. How are treatments sequenced? 8. How are the treatments different from other NETs? 9. What are some exciting new treatments in the pipeline for small bowel NETs? What are clinical trials we should be aware of for small bowel NETs? 10. How are small bowel NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for small bowel NETs? Bonus: What words of hope would you like to share with the NET community? RESOURCES WATCH https://www.youtube.com/watch?v=sZIVip3CIxI "Systemic Therapy: GI NET" - 2020 LACNETS Patient Education Conference https://www.youtube.com/watch?v=9N9QPcoLF2s Recording of Dr. Zhen Visiting the LACNETS Support Group https://www.youtube.com/watch?v=VhWI-yBXHYw Patient Story: From Diagnosis to Patient Advocacy - 2022 LACNETS NET Patient Conference https://www.youtube.com/watch?v=aNY8oejLIKI NET Patient shares how she has learned not just to survive, but also to thrive . LISTEN Listen to the NETRF NETWise Special Episode: Small Bowel NET + Take the LACNETS Quiz READ 2017 The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society 2017 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) << Back Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) CLINICALTRIALS.GOV IDENTIFIER: NCT05997056 DRUG/TREATMENT: IV PHASE: 2 STATUS: Recruiting SPONSOR: Aadi Bioscience, Inc. DESCRIPTION: https://www.youtube.com/watch?v=DbA55lS1dhk Dr. Scott Paulson Discusses the Nab-sirolimus Trial This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aadi Bioscience Medical Information EMAIL: MedInfo@aadibio.com PHONE: 1-888-246-2234 Locations: Recruiting: United States at Texas Oncology in Dallas, Texas 75246 Contact: Christine Terraciano at christine.terraciano@usoncology.com Principal Investigator: Scott Paulson, MD Recruiting: United States at Hoag Memorial Hospital Presbyterian in Newport Beach, California 92663 Contact: Jason Ledesma at jason.ledesma@hoag.org Principal investigator: Michael Demeure, MD Not Yet Recruiting: United States, Denver, Colorado 80218

CDK4/6 Abemaciclib GEP-NETS << Back Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT03891784 DRUG/TREATMENT: abemaciclib PHASE: 2 STATUS: Recruiting SPONSOR: University of Washington Collaborator: Eli Lilly and Company https://www.youtube.com/watch?v=nzR8G_0DLQo Dr. Heloisa Soares Discusses CDK4/6 abemaciclib GEP-NETS DESCRIPTION: This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: David B. Zhen, MD Fred Hutch/University of Washington Cancer Consortium EMAIL : dbzhen@uw.edu

Join NCF for Apr2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=JkH2Jsvc1Co Download the Transcript Here >>> ABOUT Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. ABOUT DR. EDWARD WOLIN DR. Edward Wolin Professor of Medicine, Medical Oncology, Icahn School of Medicine Director, Center for Carcinoid and Neuroendocrine Tumors Tisch Cancer Institute, Mount Sinai Health System Dr. Edward M. Wolin is an internationally renowned authority on neuroendocrine tumors. Dr. Wolin is the Director of the Center for Carcinoid and Neuroendocrine Tumors at the Tisch Cancer Institute at Mount Sinai and Professor of Medicine, Medical Oncology at the Icahn School of Medicine at Mount Sinai. The multidisciplinary Center for Carcinoid and Neuroendocrine Tumors features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Cancer Center. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest Carcinoid and Neuroendocrine Tumor Programs in the country, and subsequently directed the Neuroendocrine Tumor Program at University of Kentucky. Dr. Wolin is also the Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He has published in many prestigious journals, including the New England Journal of Medicine and Journal of Clinical Oncology, and is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology. During Dr. Wolin’s two decades at Cedars-Sinai Medical Center in Los Angeles, he developed a close friendship with LACNETS founder Giovanna Joyce Imbesi. Dr. Wolin was instrumental in the co-founding and development of LACNETS. LACNETS has always been very dear to his heart and he cherishes and honors the memory of Giovanna. Dr. Wolin earned his medical degree from Yale School of Medicine. He completed both his residency in internal medicine and fellowship in medical oncology at Stanford University Hospital. He was also a clinical fellow at the National Cancer Institute of the National Institutes of Health. Dr. Wolin is board certified in internal medicine and medical oncology. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

WEEKLY Virtual NET Support Group Meetings Wednesday, August 12th 12:00 - 1:30 PM Pacific Register We provide a welcoming space to come together virtually for knowledge sharing and community support. The focus of the meeting is to connect with others living with, or supporting someone living with, Neuroendocrine Tumor (NET). Both patients & caregivers discuss treatments, symptoms, living well and information uniquely related to this disease. This group is open to NET patients and caregivers. Join us via Zoom every Wednesday at 12 -1:30 PM Pacific Time. Before the live support meeting, please be sure to download Zoom on your preferred device: zoom.us/download Click here to watch a tutorial on how to download and join Zoom. *Please note all Zoom meeting details will be emailed to you within 24 hours of your registration. Questions? Email events@ncf.net . *Limited spots available. NET Support Group Registratin Register THANKS TO OUR SUPPORTERS

Learn about functional NETs, the hormones they produce, and the symptoms they can cause. Explore resources for symptom management and treatment! Understanding Functional NETs and Their Symptoms WATCH The Latest in the Management of Functional Neuroendocrine Cancers Jan 21, 2026 Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments such as adrenal insufficiency. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Watch EXPLORE Symptom Tracking Tool Evernote Download Here